Small molecule antagonists of integrin receptors

Current Medicinal Chemistry

Volumn 17, Issue 22, 2010, Pages 2371-2392

  Perdih, A ^a   Sollner Dolenc, M ^b  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Dual multiple antagonists; Fibrinogen ( IIb 3) receptor; Fibronectin ( 5 1) receptor; Integrin receptors; Small molecule antagonists; Vitronectin ( V 3) receptor

Indexed keywords

3 (2',5' DICHLOROBIPHENYL 4 YL) 2 [[[1 (2 METHOXYBENZOYL)PIPERIDIN 3 YL]CARBONYL]AMINO]PROPANOIC ACID; 4 (ISOINDOLINE 5 YL)AMINO 4 OXOBUTYRIC ACID; 7 AMINO 1,2,3,4 TETRAHYDROISOQUINOLINE; ABCIXIMAB; ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; CILENGITIDE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN RECEPTOR; INTEGRIN RECEPTOR ANTAGONIST; LOTRAFIBAN; NATALIZUMAB; PEPTIDOMIMETIC AGENT; PROTEIN INHIBITOR; RECOMBINANT HIRUDIN; SB 273005; SC 68448; SJ 749; ST 1646; TIROFIBAN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ACUTE CORONARY SYNDROME; ALLERGIC RHINITIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BINDING AFFINITY; BLOOD CLOT LYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LEYDIG CELL TUMOR; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACOPHORE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN FUNCTION; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTEGRINS; RECEPTORS, FIBRINOGEN; RECEPTORS, VITRONECTIN;

EID: 77955613373     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791698558     Document Type: Article

References (136)

1. Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. Cell, 2002, 110, 673-687.
2. Fernandez, C.; Clark, K.; Burrows, L.; Schofield, N.R.; Humphries, M.J. Regulation of the extracellular ligand binding activity of integrins. Front. Biosci., 1998, 3, 684-700.
3. Coller, B.S.; Shattil, S.J. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood, 2008, 112, 3011-3025.
4. Silva, R.; D'Amico, G.; Hodivala-Dilke, K.M.; Reynolds, L.E. Integrins: the keys to unlocking angiogenesis. Arterioscler. Thromb. Vasc. Biol., 2008, 10, 1703-1713.
5. Mousa, S.A. αv vitronectin receptors in vascular-mediated disorders. Med. Res. Rev., 2003, 23, 190-199.
6. 1 and protein kinase A. J. Biol. Chem., 2000, 275, 33920-33928.
7. 1 integrins. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 4766-4771.
8. Nadrah, K.; Sollner Dolenc, M. Dual Antagonists of Integrins. Curr. Med. Chem., 2005, 12, 1449-1466.
9. Plow, E.F.; Haas, T.A.; Zhang, L.; Loftus, J.; Smith, J.W. Ligand binding to integrins. J. Biol. Chem., 2000, 275, 21785-21788.
10. Takagi, J.; Petre, B.M.; Walz, T.; Springer, T.A. Global conformational rearrangements in integrin extracellular domains in outsidein and inside-out signaling. Cell, 2002, 110, 599-611.
11. Ginsberg, M.H.; Partridge, A.; Shattil, S.J. Integrin regulation. Curr. Opin. Cell. Biol., 2005, 17, 509-516.
12. Luo, B.-H.; Springer, T.A. Integrin structures and conformational signaling Curr. Opin. Cell Biol., 2006, 18, 579-586.
13. Liddington, R.C.; Ginsberg, M.H. Integrin activation takes shape. J. Cell. Biol., 2002, 158, 833-839.
14. Calzada, M.J.; Alvarez, M.V.; Gonzalez-Rodriguez, J. Agonistspecific structural rearrangements of integrin alpha IIbbeta 3. Confirmation of the bent conformation in platelets at rest and after activation. J. Biol. Chem., 2002, 277, 39899-39908.
15. Humphries M.J.; Symonds, E.J.; Mould, A.P. Mapping functional residues onto integrin crystal structures. Curr. Opin. Struct. Biol., 2003, 13, 236-243.
16. Humphries M.J. Insights into integrin-ligand binding and activation from the first crystal structure. Arthritis Res., 2002, 4, (Suppl 3), 69-78.
17. Xiong, J.P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D.L.; Joachimiak, A.; Goodman, S.L.; Arnaout, M.A. Crystal structure of the extracellular segment of integrin aaVVVV. Science, 2001, 294, 339-345.
18. Xiong, J.P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S.L.; Arnaout, M.A. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly- Asp ligand. Science, 2002, 296, 151-155.
19. Xiao, T.; Takagi, J.; Coller, B.S.; Wang, J.H.; Springer, T.A. Structural basis for allostery in integrins and binding to fibrinogenmimetic therapeutics. Nature, 2004, 432, 59-67.
20. Figure was made using LigandScout software: Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 2005, 45, 160-169.
21. Takagi, J., Springer, T.A. Integrin activation and structural rearrangement. Immunol. Rev., 2002, 186, 141-163.
22. Takagi, J.; Strokovich, K.; Springer, T.A.; Walz, T. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J, 2003, 22, 4607-4615.
23. Shimaoka, M.; Springer, T.A. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. 2003, 2, 703-716.
24. Ferguson, J. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes. J. Invasive. Cardiol., 2004, 16, 136-144.
25. Mousa, S.A. Alpha nu vitronectin receptors in vascular-mediated disorders. Med. Res. Rev., 2003, 23, 190-199.
26. Tilley, J.W.; Chen, L.; Sidduri, A.; Fotouhi, N. The discovery of VLA-4 antagonists. Curr. Top. Med. Chem., 2004, 4, 1509-1523.
27. Singh, J.; Adams, S.; Carter, M.B.; Cuervo, H.; Lee, W.C.; Lobb, R.R.; Pepinsky, R.B.; Petter, R.; Scott, D. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr. Top. Med. Chem., 2004, 4, 1497-1507.
28. Scarborough, R.M. Structure-activity relationships of beta-amino acid-containing integrin antagonists. Curr. Med. Chem., 1999, 6, 971-981.
29. Ojima, I.; Chakravarty, S.; Dong, Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg. Med. Chem., 1995, 3, 337-360.
30. Andronati, S.A.; Karaseva, T.L.; Krysko, A.A. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr. Med. Chem., 2004, 11, 1183-1211.
31. Tamhane, U.U.; Gurm, H.S. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin. Drug Saf., 2008, 7, 809-819.
32. Scarborough, R.M. Development of eptifibatide. Am. Heart J., 1999, 138, 1093-1104.
33. Harrington, R.A.; and collaborators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med., 1998, 339, 436-443.
34. Bazzino, O.; Barrero, C.; Garre, L.; Sosa, A.; Aylward, P.; Slany, J.; Beaudry, P.; Bedard, J.; DeLarochelliere, R.; Nguyen, M.; Bogaty, P.; Boudreault, J.R.; Diodati, J.G.; Dupuis, J.; Fitchett, D.; Fung, A.; Gervais, P.; Gossard, D.; Grandmont, D.; Huynh, T.; Kouz, S.; Langer, A.; Laramee, P.; Lemay, M.; Maillette, S.; Maranda, C.; Nasmith, J.; Pesant, Y.; Phanuef, D.; Proulx, G.; Ruel, M.; Thompson, C.; Corbalan, R.; Botero, R.; Husted, S.; Heikkila, J.; Charbonnier, B.; Moguel, R.; Commerford, P.; Landless, P.; Weich, D.; Maritz, F.; Marx, J.; Fernandes, F.; Lidon, R.; Sanz, G.; Bosch, X.; Moccetti, T.; Ali, N.; Anderson, H.V.; Bajwa, T.; Borzak, S.; Boyek, T.; Brewer, D.; Cambier, P.; Chivukula, S.; Corder, C.; Ezekowitz, M.; Feldman, R.; Glickman, L.; Jang, I.K.; Klein, M.; Korn, D.; Kraus, S.; Kwan, T.; Mann, J.T.; Marshall, J.; Martin, J.; Monrad, E.S.; Mueller, H.; Penny, W.; Schmedtje, J.; Strony, J.; Armstrong, P.; DeCani, J.; Hirsh, J.; Pepine, C.; Ryan, T. J.; Theroux, P.; Catella-Lawson, F.; Diodati, J.; Roy, L.; Willerson, J.T.; Yusuf, S.; Zhao, X.; Sax, F.L.; Harris, K.H.; Pelletier, G.; Davies, R.; Flather, M.; Gosselin, G.; Herrmann, H.; Kells, C.; Knudtson, M.; Thadani, U.; Snapinn, S.M.; Ghannam, A.; Haggert, B.; Watson, A.; Lis, J.; Brancato, C.; Fong, D. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N. Engl. J. Med., 1998, 338, 1488-1497.
35. Cannon, C.P. Oral platelet glycoprotein IIb/IIIa receptor inhibitorspart I. Clin. Cardiol., 2003, 26, 358-364.
36. Krysko, A.A.; Chugunov, B.M.; Malovichko, O.L.; Andronati, S.A.; Kabanova, T.A.; Karaseva, T.L.; Kiriyak, A.V. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid. Bioorg. Med. Chem. Lett., 2004, 14, 5533-5535.
37. Malovichko, O.L.; Petrus, A.S.; Krysko, A.A.; Kabanova, T.A.; Andronati, S.A.; Karaseva, T.L.; Kiriyak, A.V. Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 5294-5297.
38. 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study. Eur. J. Med. Chem., 2005, 40, 25-49.
39. Stefanic Anderluh, P.; Anderluh, M.; Ilas, J.; Mravljak, J.; Sollner Dolenc, M.; Stegnar, M.; Kikelj, D. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities. J. Med. Chem., 2005, 48, 3110-3113.
40. Ilas, J.; Jakopin, Z.; Borstnar, T.; Stegnar, M.; Kikelj, D. 3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function. J. Med. Chem., 2008, 51, 5617-5629.
41. Bi, Q.; Zhou, X.; Cen, X.; Qu, H.; Luo, J.; Huang, Y.; Zhu, S. Efficient targeted anticoagulant with active RGD motif. Thromb. Res., 2007, 120, 541-547.
42. Lark, M.W.; Stroup, G.B.; Hwang, S.M.; James, I.E.; Rieman, D.J.; Drake, F.H.; Bradbeer, J.N.; Mathur, A.; Erhard, K.F.; Newlander, K.A.; Ross, S.T.; Salyers, K.L.; Smith, B.R.; Miller, W.H.; Huffman, W.F.; Gowen, M. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J. Pharmacol. Exp. Ther., 1999, 291, 612-617.
43. Storgard, C.M.; Stupack, D.G.; Jonczyk, A.; Goodman, S.L.; Fox, R.I.; Cheresh, D.A. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest., 1999, 103, 47-54.
44. Hood, J.D.; Cheresh, D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer, 2002, 2, 91-100.
45. Mitjans, F.; Meyer, T.; Fittschen, C.; Goodman, S.; Jonczyk, A.; Marshall, J.F.; Reyes, G.; Piulats, J. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int. J. Cancer., 2000, 87, 716-723.
46. Sorbera, L.A.; Graul, A.; Castaner, J. Cilengitide. Drugs Fut., 2000, 25, 674-678.
47. Badger, A.M.; Blake, S.; Kapadia, R.; Sarkar, S.; Levin, J.; Swift, B. A.; Hoffman, S.J.; Stroup, G.B.; Miller, W.H.; Gowen, M.; Lark, M.W. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum., 2001, 44, 128-137.
48. Feuston, B.P.; Culberson, J.C.; Duggan, M.E.; Hartman, G.D.; Leu, C.T.; Rodan, S.B. Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin. J. Med. Chem., 2002, 45, 5640-5648.
49. Marinelli, L.; Lavecchia, A.; Gottschalk, K.E.; Novellino, E.; Kessler, H. Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design. J. Med. Chem., 2003, 46, 4393-4404.
50. Belvisi, L.; Bernardi, A.; Colombo, M.; Manzoni, L.; Potenza, D.; Scolastico, C.; Giannini, G.; Marcellini, M.; Riccioni, T.; Castorina, M.; LoGiudice, P.; Pisano, C. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg. Med. Chem., 2006, 14, 169-180.
51. Banfi, L.; Basso, A.; Damonte, G.; De Pellegrini, F.; Galatini, A.; Guanti, G.; Monfardini, I.; Riva, R.; Scapolla, C. Synthesis and biological evaluation of new conformationally biased integrin ligands based on a tetrahydroazoninone scaffold. Bioorg. Med. Chem. Lett., 2007, 17, 1341-1345.
52. 3 integrin receptor. Tetrahedron Lett., 2001, 42, 7387-7391.
53. Gentilucci, L.; Cardillo, G.; Squassabia, F.; Tolomelli, A.; Spampinato, S.; Sparta, A.; Baiula, M. Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg. Med. Chem. Lett., 2007, 17, 2329-2333.
54. 3 Antagonists. J. Am. Chem. Soc., 1996, 118, 7461-7472.
55. Iwama, S.; Kitano, T.; Fukuya, F.; Honda, Y.; Sato, Y.; Notake, M.; Morie, T. Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model. Bioorg. Med. Chem. Lett., 2004, 14, 2567-2570.
56. 3 through structure-based virtual screening. Bioorg. Med. Chem. Lett., 2006, 16, 5878-5882.
57. Dayam, R.; Aiello, F.; Deng, J.; Wu, Y.; Garofalo, A.; Chen, X.; Neamati, N. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. J. Med. Chem., 2006, 49, 4526-4534.
58. Urbahns, K.; Härter, M.; Albers, M.; Schmidt, D.; Stelte-Ludwig, B.; Brüggemeier, U.; Vaupel, A.; Gerdes, C. Biphenyls as potent vitronectin receptor antagonists Bioorg. Med. Chem. Lett., 2002, 12, 205-208.
59. Urbahns, K.; Härter, M.; Vaupel, A.; Albers, M.; Schmidt, D.; Brüggemeier, U.; Stelte-Ludwig, B.; Gerdes, C.; Tsujishita, H. Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas. Bioorg. Med. Chem. Lett., 2003, 13, 1071-1074.
60. Urbahns, K.; Härter, M.; Albers, M.; Schmidt, D.; Stelte-Ludwig, B.; Brüggemeier, U.; Vaupel, A.; Keldenich, J.; Lustig, K.; Tsujishita, H.; Gerdes, C. Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides. Bioorg. Med. Chem. Lett., 2007, 17, 6151-6154.
61. 3 inhibits leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res., 1998, 58, 1930-1935.
62. 3 receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14, 1471-1476.
63. 3 receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 839-844.
64. 3 integrin receptor antagonists with improved oral pharmacokinetic properties. Bioorg. Med. Chem. Lett., 2006, 16, 845-849.
65. Penning, T.D.; Khilevich, A.; Chen, B.B.; Russell, M.A.; Boys, M.L.; Wang, Y.; Duffin, T.; Engleman, V.W.; Finn, M.B.; Freeman, S.K.; Hanneke, M.L.; Keene, J.L.; Klover, J.A.; Nickols, G.A.; Nickols, M.A.; Rader, R.K.; Settle, S.L.; Shannon, K.E.; Steininger, C.N.; Westlin, M.M.; Westlin, W.F. Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 3156-3161.
66. 221st ACS National Meeting, San Diego, 2001; MEDI-225.
67. Nagarajan, S.R.; Devadas, B.; Malecha, J.W.; Lu, H.F.; Ruminski, P.G.; Rico, J.G.; Rogers, T.E.; Marrufo, L.D.; Collins, J.T.; Kleine, H.P.; Lantz, M.K.; Zhu, J.; Green, N.F.; Russell, M.A.; Landis, B.H.; Miller, L.M.; Meyer, D.M.; Duffin, T.D.; Engleman, V.W.; Finn, M.B.; Freeman, S.K.; Griggs, D.W.; Williams, M.L.; Nickols, M.A.; Pegg, J.A.; Shannon, K.E.; Steininger, C.; Westlin, M.M.; Nickols, G.A. Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model. Bioorg. Med. Chem. Lett., 2004, 14, 2567-2570.
68. Nagarajan, S.R.; Lu, H.F.; Gasiecki, A.F.; Khanna, I.K.; Parikh, M.D.; Desai, B.N.; Rogers, T.E.; Clare, M.; Chen, B.B.; Russell, M.A.; Keene, J.L.; Duffin, T.; Engleman, V.W.; Finn, M.B.; Freeman, S.K.; Klover, J.A.; Nickols, G.A.; Nickols, M.A.; Shannon, K.E.; Steininger, C.A.; Westlin, W.F.; Westlin, M.M.; Williams, M.L. Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization. Bioorg. Med. Chem., 2007, 15, 3390-3412.
69. Coleman, P.J.; Askew, B.C.; Hutchinson, J.H.; Whitman, D.B.; Perkins, J.J.; Hartman, G.D.; Rodan, G.A.; Leu, C.T.; Prueksaritanont, T.; Fernandez-Metzler, C.; Merkle, K.M.; Lynch, R.; Lynch, J.J.; Rodan, S.B.; Duggan, M.E. Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics. Bioorg. Med. Chem. Lett., 2002, 12, 2463-2465.
70. Coleman, P.J.; Brashear, K.M.; Hunt, C.A.; Hoffman, W.F.; Hutchinson, J.H.; Breslin, M.J.; McVean, C.A.; Askew, B.C.; Hartman, G.D.; Rodan, S.B.; Rodan, G.A.; Leu, C.T.; Prueksaritanont, T.; Fernandez-Metzler, C.; Ma, B.; Libby, L.A.; Merkle, K.M.; Stump, G. L.; Wallace, A.A.; Lynch, J.J.; Lynch, R.; Duggan, M.E. Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements. Bioorg. Med. Chem. Lett., 2002, 12, 31-34.
71. Hutchinson, J.H.; Halczenko, W.; Brashear, K.M.; Breslin, M.J.; Coleman, P.J.; Duong, le T.; Fernandez-Metzler, C.; Gentile, M.A.; Fisher, J.E.; Hartman, G.D.; Huff, J.R.; Kimmel, D.B.; Leu, C.T.; Meissner, R.S.; Merkle, K.; Nagy, R.; Pennypacker, B.; Perkins, J.J.; Prueksaritanont, T.; Rodan, G.A.; Varga, S.L.; Wesolowski, G.A.; Zartman, A.E.; Rodan, S.B.; Duggan, M.E. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J. Med. Chem., 2003, 46, 4790-4798.
72. Wang, J.; Breslin, M.J.; Coleman, P.J.; Duggan, M.E.; Hunt, C.A.; Hutchinson, J.H.; Leu, C.-T.; Rodan, S.B.; Rodan, G.A.; Hartman, G.D. Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 1049-1052.
73. Brashear, K.M.; Hunt, C.A.; Kucer, B.T.; Duggan, M.E.; Hartman, G.D.; Rodan, G.A.; Rodan, S.B.; Leu, C.-T.; Prueksaritanont, T.; Fernandez-Metzler, C.; Barrish, A.; Homnick, C.F.; Hutchinson, J.H.; Coleman, P.J. Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl betaamino acids as aspartic acid replacements. Bioorg. Med. Chem. Lett., 2002, 12, 3483-3486.
74. Coleman, P.J.; Brashear, K.M.; Askew, B.C.; Hutchinson, J.H.; McVean, C.A.; Duong le, T.; Feuston, B.P.; Fernandez-Metzler, C.; Gentile, M.A.; Hartman, G.D.; Kimmel, D.B.; Leu, C.T.; Lipfert, L.; Merkle, K.; Pennypacker, B.; Prueksaritanont, T.; Rodan, G.A.; Wesolowski, G.A.; Rodan, S.B.; Duggan, M.E. Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis. J. Med. Chem., 2004, 47, 4829-4837.
75. Holtkötter, O.; Nieswandt, B.; Smyth, N.; Müller, W.; Hafner, M.; Schulte, V.; Krieg, T.; Eckes, B. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J. Biol. Chem., 2002, 277, 10789-10794.
76. Guo, W.; Giancotti, F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol., 2004, 5, 816-826.
77. Hagmann, W.K.; Durette, P.L.; Lanza, T.; Kevin, N.J.; de Laszlo, S.E.; Kopka, I.E.; Young, D.; Magriotis, P.A.; Li, B.; Lin, L. S.; Yang, G.; Kamenecka, T.; Chang, L.L.; Wilson, J.; MacCoss, M.; Mills, S.G.; Van Riper, G.; McCauley, E.; Egger, L.A.; Kidambi, U.; Lyons, K.; Vincent, S.; Stearns, R.; Colletti, A.; Teffera, J.; Tong, S.; Fenyk-Melody, J.; Owens, K.; Levorse, D.; Kim, P.; Schmidt, J.A.; Mumford, R.A. The discovery of sulfonylated dipeptides as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett., 2001, 11, 2709-2713.
78. Xue, C.-B.; Rafalski, M.; Roderick, J.; Eyermann, C.J.; Mousa, S.; Olson R.E.; DeGrado, W.F. Design, synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors. Bioorg. Med. Chem. Lett., 1996, 6, 339-344.
79. Choi, S.; Vilaire, G.; Marcinkiewicz, C.; Winkler, J.D.; Bennett, J.S.; DeGrado, W.F. Small molecule inhibitors of integrin alpha2beta1. J. Med. Chem., 2007, 50, 5457-5462.
80. Francis, S.E.; Goh, K.L.; Hodivala-Dilke, K.; Bader, B.L.; Stark, M.; Davidson, D.; Hynes, R.O. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 927-933.
81. Kim, S.; Bell, K.; Mousa, S.A.; Varner, J.A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol., 2000, 156, 1345-1362.
82. Brower, V. Tumor angiogenesis--new drugs on the block. Nat. Biotechnol., 1999, 17, 963-968.
83. Marinelli, L.; Meyer, A.; Heckmann, D.; Lavecchia, A.; Novellino, E.; Kessler, H. Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists. J. Med. Chem., 2005, 48, 4204-4207.
84. Stragies, R.; Osterkamp, F.; Zischinsky, G.; Vossmeyer, D.; Kalkhof, H.; Reimer, U.; Zahn, G. Design and synthesis of a new class of selective integrin alpha5beta1 antagonists. J. Med. Chem., 2007, 50, 3786-3794.
85. Heckmann, D.; Meyer, A.; Marinelli, L.; Zahn, G.; Stragies, R.; Kessler, H. Probing integrin selectivity: rational design of highly active and selective ligands for the alpha5beta1 and alphavbeta3 integrin receptor. Angew. Chem. Int. Ed. Engl., 2007, 46, 3571-3574.
86. Harris, E.S.; McIntyre, T.M.; Prescott, S.M.; Zimmerman, G.A. The leukocyte integrins. J. Biol. Chem., 2000, 275, 23409-23412.
87. Gottlieb, A.B.; Bos, J.D. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immunol., 2002, 105, 105-116.
88. Shimaoka, M.; Salas, A.; Yang, W.; Weitz-Schmidt, G.; Springer, T.A. Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity, 2003, 19, 391-402.
89. Kallen, J.; Welzenbach, K.; Ramage, P.; Geyl, D.; Kriwacki, R.; Legge, G.; Cottens, S.; Weitz-Schmidt, G.; Hommel, U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a Idomain. J. Mol. Biol., 1999, 292, 1-9.
90. Burdick, D.J.; Gadek, T.R.; Mcdowell, R.S.; Marsters, J.; Oare, D.A.; Reynolds, M.E.; Stanley, M.S. Weese, K.J. Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders. PCT Int. Appl. WO 9949856, October 7, 1999.
91. Burdick, D.J.; Gadek, T.R.; Marsters, J.; Oare, D.A.; Reynolds, M.E.; Stanley, M.S. LFA-1 antagonist compounds. PCT Int. Appl. WO 02059114, August 01, 2002.
92. Fotouhi, N.; Gillespie, P.; Guthrie, R.; Pietranico-Cole, S.; Yun, W. Diaminopropionic acid derivatives. PCT Int. Appl. WO 0021920, April 20, 2000.
93. Fotouhi, N.; Gillespie, P.; Guthrie, R.; Pietranico-Cole, S.; Yun, W. Dehydroamino acids. PCT Int. Appl. WO 0158853, August 16, 2001.
94. 2. J. Biol. Chem., 2006, 281, 37904-37912.
95. Yusuf-Makagiansar, H.; Anderson, M.E.; Yakovleva, T.V.; Murray, J.S.; Siahaan, T.J. Inhibition of LFA-1/ICAM-1 and VLA- 4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev., 2002, 22, 146-167.
96. von Andrian, U.H.; Engelhardt, B. α4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med., 2003, 348, 68-72.
97. Miller, D.H.; Khan, O.A.; Sheremata, W.A.; Blumhardt, L.D.; Rice, G.P.; Libonati, M.A.; Willmer-Hulme, A.J.; Dalton, C.M.; Miszkiel, K.A.; O'Connor, P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2003, 348, 15-23.
98. Tilley, J.W.; Sidduri, A. VLA-4 antagonists. Drugs Future, 2001, 26, 985-998.
99. Yang, G.X.; Hagmann, W.K. VLA-4 antagonists: potent inhibitors of lymphocyte migration. Med. Res. Rev., 2003, 23, 369-392.
100. Jackson, D.Y. Alpha 4 integrin antagonists. Curr. Pharm. Des., 2002, 8, 1229-1253.
101. Porter, J.R.; Archibald, S.C.; Brown, J.A.; Childs, K.; Critchley, D.; Head, J.C.; Hutchinson, B.; Parton, T.A.; Robinson, M.K.; Shock, A.; Warrellow, G.J.; Zomaya, A. Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists. Bioorg. Med. Chem. Lett., 2002, 12, 1591-1594.
102. Porter, J.R.; Archibald, S.C.; Brown, J.A.; Childs, K.; Critchley, D.; Head, J.C.; Parton, T.A.; Robinson, M.K.; Shock, A.; Taylor, R.J.; Warrellow, G.J. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists. Bioorg. Med. Chem. Lett., 2003, 13, 805-808.
103. Okigami, H.; Takeshita, K.; Tajimi, M.; Komura, H.; Albers, M.; Lehmann, T.E.; Rölle, T.; Bacon, K.B. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Eur. J. Pharmacol., 2007, 559, 202-209.
104. Vincent, A.M.; Cawley, J.C.; Burthem, J. Integrin function in chronic lymphocytic leukemia. Blood, 1996, 87, 4780-4788.
105. Peng, L.; Liu, R.; Marik, J.; Wang, X.; Takada, Y.; Lam, K.S. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat. Chem. Biol., 2006, 2, 381-389.
106. 1 Integrin. J. Med. Chem., 2007, 50, 5863-5867.
107. Feagan, B.G.; Greenberg, G.R.; Wild, G.; Fedorak, R.N.; Paré, P.; McDonald, J.W.; Dubé, R.; Cohen, A.; Steinhart, A.H.; Landau, S.; Aguzzi, R.A.; Fox, I.H.; Vandervoort, M.K. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med., 2005, 352, 2499-2507.
108. 4 integrin receptor antagonists. J. Med. Chem., 2006, 49, 3402-3411.
109. Muro, F.; Iimura, S.; Yoneda, Y.; Chiba, J.; Watanabe, T.; Setoguchi, M.; Iigou, Y.; Takayama, G.; Yokoyama, M.; Takashi, T.; Nakayama, A.; Machinaga, N. Identification of 4-[1-[3-chloro-4-[N'- (5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)- pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg. Med. Chem., 2008, 16, 9991-10000.
110. Gutteridge, C.E.; de Laszlo, S.E.; Kamenecka, T.M.; McCauley, E.; van Riper, G.; Mumford, R.A.; Kidambi, U.; Egger, L.A.; Tong, S.; Hagmann, W.K. N-(3-Phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists. Bioorg. Med. Chem. Lett., 2003, 13, 885-890.
111. Fujita, M.; Seki, T.; Inada, H.; Shimizu, K.; Takahama, A.; Sano, T. Novel Agents Combining Platelet Activating Factor (PAF) Receptor Antagonist with Thromboxane Synthase Inhibitor (TxSI). Bioorg. Med. Chem. Lett., 2002, 12, 771-774.
112. Rotondo, S.; Dell'Elba, G.; Manarini, S.; Cerletti, C.; Evangelista, V. The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit. Eur. J. Pharm., 2006, 546, 95-101.
113. Tam, S.H.; Sassoli, P.M.; Jordan, R.E.; Nakada, M.T. Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and FFvß3 Integrins. Circulation, 1998, 98, 1085-1091.
114. 3 dual antagonistic activity. Bioorg. Med. Chem., 2006, 14, 2089-2108.
115. 3 dual antagonists. Bioorg. Med. Chem., 2006, 14, 2109-2130.
116. 3 dual activity and improved water solubility. Bioorg. Med. Chem., 2006, 14, 2131-2150.
117. 3 selectivity by meta-oriented substitution Bioorg. Med. Chem., 2006, 14, 4158-4181.
118. Max, R.; Gerritsen, R.R.; Nooijen, P.T.; Goodman, S.L.; Sutter, A.; Keilholz, U.; Ruiter, D.J.; De Waal, R.M. Immunohistochemical analysis of integrin aavvvvvexpression on tumor-associated vessels of human carcinomas. Int. J. Cancer., 1997, 71, 320-324.
119. Henry, C.; Moitessier, N.; Chapleur, Y. Vitronectin receptor -[[VVVV integrin- antagonists: chemical and structural requirements for activity and selectivity. Mini Rev. Med. Chem., 2002, 2, 531-542.
120. 5: Homology modeling and ligand binding. J. Med. Chem., 2004, 47, 4166-4177.
121. 5 integrin ligand conjugates: regioselective solid-phase functionalisation of an RGD based peptide. Tetrahedron Lett., 2001, 42, 2787-2790.
122. Perdih, A.; Kikelj, D. The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics. Curr. Med. Chem., 2006, 13, 1525-1556.
123. Kumar, S.; Wang, Q.; Sasaki, N.A. Synthesis of conformationally constrained analogues of RGD tripeptide. Tetrahedron, 2007, 63, 2084-2094.
124. v integrin antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 3291-3296.
125. Marugán, J.J.; Manthey, C.; Anaclerio, B.; Lafrance, L.; Lu, T.; Markotan, T.; Leonard, K.A.; Crysler, C.; Eisennagel, S.; Dasgupta, M.; Tomczuk, B. Design, synthesis, and biological evaluation of Novel Potent and Selective oovvv3/33vvv5 Integrin dual inhibitors with improved bioavailability. Selection of the molecular core. J. Med. Chem., 2005, 48, 926-934.
126. 5 integrin dual antagonists with reduced binding affinity for human serum albumin. Eur. J. Med. Chem., 2006, 41, 847-861.
127. 3 antagonist using structure-based drug design. Eur. J. Med. Chem., 2007, 42, 334-343.
128. 5. Bioorg. Med. Chem. Lett., 2009, 19, 353-355.
129. 3 integrins on smooth muscle cell spreading and migration in fibrin gels. Thromb. Haemost., 2000, 84, 701-705.
130. Bubenik, M.; Meerovitch, K.; Bergeron, F.; Attardo, G.; Chan, L. Thiophene-based vitronectin receptor antagonists. Bioorg. Med. Chem. Lett., 2003, 13, 503-506.
131. 1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vasc. Pharm., 2003, 40, 77-89.
132. Smallheer, J.M.; Weigelt, C.A.; Woerner, F.J.; Wells, J.S.; Daneker, W.F.; Mousa, S. A.; Wexler, R.R.; Jadhav, P.K. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorg. Med. Chem. Lett., 2004, 14, 383-387.
133. 1 integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds. Bioorg. Med. Chem., 2007, 15, 7380-7390.
134. 7 integrins. Bioorg. Med. Chem. Lett., 2002, 12, 133-136.
135. 7 integrin receptor antagonists. Bioorg. Med. Chem., 2005, 13, 6693-6702.
136. 4 integrin antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 1331-1335.